摘要
目的研究慢性阻塞性肺疾病的患者血清中Clara细胞分泌蛋白CC16和SP-D水平与患者肺功能的关系。方法选取在2013年12月至2014年12月之间,随机选择我院呼吸内科住院及门诊受试患者。将患者随机分为三组,A组为COPD的急性加重期(AECOPD)患者组(n=25),B组为COPD稳定期患者组(n=25),C组为非COPD对照组(n=25)。收集患者及对照组临床资料和血清标本,采用ELISA法测定血清CC16、SP-D水平。检测受试者第一秒钟用力呼气量占预计值的百分比(FEV1%)、FEV1和用力肺活量的比值(FEV1/FVC)、肺一氧化碳弥散量占预计值百分比(DLCO%)。结果COPD的急性加重期患者血清中Clara细胞分泌蛋白(CC16)水平最低,其次是COPD稳定期患者组,再次是对照组的受试者,其血清中Clara细胞分泌蛋白(CC16)水平最高(P<0.05)。COPD的急性加重期的患者血清中SP-D水平最高,其次是COPD稳定期患者组,再次是对照组的受试者,其血清中SP-D水平最低(P<0.05)。三组慢性阻塞性肺疾病的患者肺功能的变化与血清中CC16和SP-D水平密切相关,Clara细胞分泌蛋白CC16和与患者肺功能的关系:两者间均呈现出高度的一致性,呈正相关关系;SP-D水平与患者肺功能的关系:两者间均呈现出高度的反向性,呈负相关关系(P<0.05)。结论 COPD患者血清CC16降低而SP-D水平升高,Clara细胞分泌蛋白CC16和与患者肺功能呈正相关关系;SP-D水平与患者肺功能呈负相关关系。
Objective To study the relationship between serum levels of Clara cell secretory protein(CC16) and Surfactant protein D(SP-D) and pulmonary function in patients with chronic obstructive pulmonary disease(COPD).Methods Patients from our hospital were randomly divided into two groups,group A,25 patients was acute exacerbation of COPD(AECOPD).Group B,25 patients was stable COPD.Group C was non COPD control group,25 subjects.Serum CC16 and SP-D were measured by ELISA method.Forced expiratory volume(FEV1%),FEV1/FVC ratio and the percentage of carbon monoxide diffusing capacity(DLCO%) were determined by the test of forced expiratory volume in the first second.Results CC16 concentration was significantly lower in the patients with acute exacerbation of COPD when compared with stable COPD and control group(P〈0.05).The serum level of SP-D was significantly higher in AECOPD when compared with stable COPD and control group(P〈0.05).Serum levels of CC16 and SP-D were closely correlated with patient's pulmonary function.CC16 was positively correlated with patient's pulmonary function.SP-D was negatively correlated with lung function of patients(P〈0.05).Conclusion The serum CC16 in COPD patients was decreased and the SP-D concentration was increased.CC16 was positively correlated with the pulmonary function of the patients,the SP-D concentration was negatively correlated with the patient's lung function.
出处
《标记免疫分析与临床》
CAS
2016年第8期870-873,共4页
Labeled Immunoassays and Clinical Medicine